HawaiiRELATING TO TERMINAL ILLNESSES.
What it does
Authorizes manufacturers of investigational drugs or biological products that are pending approval by the United States Food and Drug Administration to make the drugs or products available to terminally ill patients under certain conditions. Effective 12/31/2050. (SD1)
Where do you stand?
Choose your position
Tell your reps
Take a position to see your representatives and ways to contact them.
Where it stands
- Introduced
- Passed Senate
- Passed House
- To Governor
- Became Law
Looking ahead
No hearings or votes scheduled.
History
- 2025
- Dec 8Carried over to 2026 Regular Session.Latest
- Feb 7Reported from HHS (Stand. Com. Rep. No. 90) with recommendation of passage on Second Reading, as amended (SD 1) and referral to CPN/JDC.
- Feb 7Report adopted; Passed Second Reading, as amended (SD 1) and referred to CPN/JDC.Minor
- Jan 29The committee(s) on HHS recommend(s) that the measure be PASSED, WITH AMENDMENTS. The votes in HHS were as follows: 5 Aye(s): Senator(s) San Buenaventura, Aquino, Hashimoto, Keohokalole, Fevella; Aye(s) with reservations: none ; 0 No(es): none; and 0 Excused: none.Minor
- Vote recorded The committee(s) on HHS recommend(s) that the measure be PASSED, WITH AMENDMENTS. Result: pass.Upper
- Jan 24The committee(s) on HHS has scheduled a public hearing on 01-29-25 1:00PM; Conference Room 225 & Videoconference.
- Jan 16Referred to HHS, CPN/JDC.Minor
- Jan 15Introduced and passed First Reading.Minor
- Jan 8Pending Introduction.Introduced